Case 1:19-md-02875-RMB-SAK Document 2750-30 Filed 06/17/24 Page 1 of 2 PageID: 103120

Exhibit 35

Document 2750-30 PageID: 103121

3月初访印度之前应完成的工作

2019/\$2/5225 12.44

Big player APL and Hetero is suffering from genotoxic impurity issues, their consumption is shifting to DRL, MSN, Mylan, Vashuda and Sun Pharma. Meanwhile there are another two new India suppliers about to supply locally. Huahai has very limit time to grab the opportunities.

JW:
Bro-otbn
India visit discuss
不影响的产品梳理
拜访华宇 准备1day 介绍情况
全面计划准备 全打一圈 都拜访
国内对手情况 和采购联动

